ETFs & Funds
Home›ETFs & Funds›Equity Funds›Lilly raises outlook for third time this year as Zepbo…
Lilly raises outlook for third time this year as Zepbound sales soar.
The drug continues do dominate the market for prescription weight-loss drugs in the U.S.
← Newer storyPutin praises Elon Musk as a ‘genius’ as Russia develops Starlink alt…Older story →Bitcoin Has Failed to Break Through Resistance, Whereas Bnb Is Gainin…
More like this
ETFs & FundsThe Fed held off on a rate hike. Today’s GDP and inflation reports could make waiting harder.
ETFs & FundsMedicare used AI to pre-approve patient care, and it immediately led to a large drop in medical services
ETFs & FundsCommodity ETFs: Beyond the Gold Trade